| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Prepaid expenses and other current assets | 108 | |||
| Cash and cash equivalents | 4,275 | |||
| Total current assets | 4,383 | |||
| Property and equipment, net | 1 | |||
| Right-of-use lease asset | 17 | |||
| Non-current deposits | 0 | |||
| Total assets | 4,401 | |||
| Accrued and other current liabilities | 539 | |||
| Accounts payable | 221 | |||
| Total current liabilities | 760 | |||
| Lease liability | 10 | |||
| Total liabilities | 770 | |||
| Accumulated deficit | -441,779 | |||
| Preferred stock, value-Series FPreferred Stock | 3 | |||
| Preferred stock, value-Series EPreferred Stock | 0 | |||
| Preferred stock, value-Series DPreferred Stock | 0 | |||
| Preferred stock, value-Series CPreferred Stock | 0 | |||
| Preferred stock, value-Series BPreferred Stock | 0 | |||
| Preferred stock, value-Series APreferred Stock | 0 | |||
| Preferred stock, value-Six Percent Convertible Exchangeable Preferred Stock | 0 | |||
| Common stock, 0.001 par value 600,000,000 shares authorized at june 30, 2025 and december 31, 2024 1,583,965 shares issued and outstanding at june 30, 2025 and 36,913 shares issued and outstanding at december 31, 2024 | 2 | |||
| Additional paid-in capital | 445,405 | |||
| Accumulated other comprehensive loss | 0 | |||
| Total stockholders equity (deficit) | 3,631 | |||
| Total liabilities and stockholders equity (deficit) | 4,401 | |||
Cyclacel Pharmaceuticals, Inc. (CYCCP)
Cyclacel Pharmaceuticals, Inc. (CYCCP)